```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS  4  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS  5  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS  6  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03   FRANCEPAT now available on STN
 NEWS  9  MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29   WPIFV now available on STN
 NEWS 11  MAR 29   No connect hour charges in WPIFV until May 1, 2004
 NEWS 12  MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004

=> file medline, uspatful, biosis, wpids, japio, fsta, jicst, biobusiness,
scisearch, ceaba, cen, embase, dgene
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 10:33:36 ON 26 APR 2004

FILE 'USPATFULL' ENTERED AT 10:33:36 ON 26 APR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'BIOSIS' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'FSTA' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOBUSINESS' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'SCISEARCH' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'CEABA-VTB' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'EMBASE' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 10:33:36 ON 26 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s albumin fusion protein () antibody
L1 6 ALBUMIN FUSION PROTEIN (W) ANTIBODY

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 6 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010134	A1	20040115	
APPLICATION INFO.:	US 2001-833245	A1	20010412	(9)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 6 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219875	A1	20031127	
APPLICATION INFO.:	US 2001-833118	A1	20010412	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 6 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Ballance, David J., Berwyn, PA, UNITED STATES		
	Sleep, Darrell, West Bridgford, UNITED KINGDOM		
	Prior, Christopher P., Rosemont, PA, UNITED STATES		
	Sadeghi, Homayoun, Doylestown, PA, UNITED STATES		
	Turner, Andrew J., Eagleville, PA, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199043	A1	20031023	
APPLICATION INFO.:	US 2001-832501	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	60
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 6 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:244853 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES		
	Sadeghi, Homayoun, Doylestown, PA, UNITED STATES		
	Prior, Christopher P., Rosemont, PA, UNITED STATES		
	Turner, Andrew J., Eagleville, PA, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 6 USPATFULL on STN
TI Chemokine beta-1 fusion proteins
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ckβ-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-γ, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143191	A1	20030731	
APPLICATION INFO.:	US 2002-153604	A1	20020524	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-293212P	20010525	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 15446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 6 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE

```
                        ---------------- ------ --------
PATENT INFORMATION:     US 2003125247      A1   20030703
APPLICATION INFO.:      US 2001-833041     A1   20010412  (9)

                               NUMBER         DATE
                        ---------------- --------
PRIORITY INFORMATION:   US 2000-256931P    20001221 (60)
                        US 2000-199384P    20000425 (60)
                        US 2000-229358P    20000412 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                        ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:       29
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     20 Drawing Page(s)
LINE COUNT:             15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,
     BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT
     10:33:36 ON 26 APR 2004
L1             6 S ALBUMIN FUSION PROTEIN () ANTIBODY

=> s HER2 antibody
L2           521 HER2 ANTIBODY

=> s albumin fusion protein and l2
L3             0 ALBUMIN FUSION PROTEIN AND L2

=> s albumin fusion protein () HER2 antibody
L4             0 ALBUMIN FUSION PROTEIN (W) HER2 ANTIBODY

=> s human epidermal growth factor receptor 2 adj albumin fusion protein
  10 FILES SEARCHED...
L5             0 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION
                 PROTEIN

=> s human epidermal growth factor
L6          6589 HUMAN EPIDERMAL GROWTH FACTOR

=> s l6 and "receptor-2"
   6 FILES SEARCHED...
L7           875 L6 AND "RECEPTOR-2"

=> s l7 and albumin
L8            91 L7 AND ALBUMIN

=> d l8 ti abs ibib 1-10

L8   ANSWER 1 OF 91  USPATFULL on STN
TI     Genomics-driven high speed cellular assays, development thereof, and
       collections of cellular reporters
AB     Methods for identifying responder genes and regulatory regions that
       confer responsiveness to a test substance or other perturbation are
       provided. Regulatory regions identified by such methods or other methods
       are cloned into expression constructs to control expression of a nucleic
       acid molecule that encodes, for example, a selectable marker or
       reporter, and introduced into cells. The resulting cells are used, for
```

example, in high throughput screening assays for profiling substances and conditions and for studying the function of the regulatory region mediating the response. Addressable collections of the cells are also provided.

ACCESSION NUMBER: 2004:101092 USPATFULL
TITLE: Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
INVENTOR(S): Caldwell, Jeremy S., Cardiff, CA, UNITED STATES
Hogenesch, John B., Encinitas, CA, UNITED STATES
Su, Andrew I., La Jolla, CA, UNITED STATES
PATENT ASSIGNEE(S): IRM, LLC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004076954	A1	20040422	
APPLICATION INFO.:	US 2002-97034	A1	20020312	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275148P	20010312 (60)
	US 2001-274979P	20010312 (60)
	US 2001-275070P	20010312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 4350 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122-1246
NUMBER OF CLAIMS: 125
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 6335

L8 ANSWER 2 OF 91 USPATFULL on STN
TI Molecular toxicology modeling
AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

ACCESSION NUMBER: 2004:94708 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072160	A1	20040415	
APPLICATION INFO.:	US 2002-152319	A1	20020522	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)
	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)

	US 2001-315047P 20010828 (60)
	US 2001-324928P 20010927 (60)
	US 2001-330867P 20011101 (60)
	US 2001-330462P 20011022 (60)
	US 2001-331805P 20011121 (60)
	US 2001-336144P 20011206 (60)
	US 2001-340873P 20011219 (60)
	US 2002-357843P 20020221 (60)
	US 2002-357842P 20020221 (60)
	US 2002-357844P 20020221 (60)
	US 2002-364134P 20020315 (60)
	US 2002-370206P 20020408 (60)
	US 2002-370247P 20020408 (60)
	US 2002-370144P 20020408 (60)
	US 2002-371679P 20020412 (60)
	US 2002-372794P 20020417 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS:	59
EXEMPLARY CLAIM:	1
LINE COUNT:	27909

L8 ANSWER 3 OF 91 USPATFULL on STN

TI Method for making humanized antibodies

AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

ACCESSION NUMBER:	2004:90568 USPATFULL
TITLE:	Method for making humanized antibodies
INVENTOR(S):	Carter, Paul J., San Francisco, CA, United States Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6719971	B1	20040413
APPLICATION INFO.:	US 2000-705392		20001102 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 146206, now patented, Pat. No. US 6407213, issued on 18 Jun 2002 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Ungar, Susan
ASSISTANT EXAMINER:	Davis, Minh Tam
LEGAL REPRESENTATIVE:	Lee, Wendy M.
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	4948

L8 ANSWER 4 OF 91 USPATFULL on STN

TI Central airway administration for systemic delivery of therapeutics

AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are

adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN-α2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fcγ1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

ACCESSION NUMBER: 2004:83456 USPATFULL
TITLE: Central airway administration for systemic delivery of therapeutics
INVENTOR(S): Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA (U.S. corporation)
Children's Medical Center Corporation, Boston, MA (U.S. corporation)
Brandeis University, Waltham, MA (U.S. corporation)
Syntonix Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063912	A1	20040401
APPLICATION INFO.:	US 2003-622108	A1	20030717 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-435608, filed on 9 May 2003, PENDING Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364482P	20020315 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Alan W. Steele, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 4477

L8 ANSWER 5 OF 91 USPATFULL on STN
TI Multivalent and multispecific binding proteins, their manufacture and use
AB Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:76622 USPATFULL
TITLE: Multivalent and multispecific binding proteins, their manufacture and use
INVENTOR(S): Holliger, Kaspar-Philipp, Cambridge, UNITED KINGDOM
Griffiths, Andrew David, Cambridge, UNITED KINGDOM
Hoogenboom, Hendricus Renerus Jacobus Matheus, Hasselt, BELGIUM
Malmqvist, Magnus, Uppsala, SWEDEN
Marks, James David, Kensington, CA, UNITED STATES
McGuinness, Brian Timothy, Cambridge, UNITED KINGDOM
Pope, Anthony Richard, Cambridge, UNITED KINGDOM
Prospero, Terence Derek, Cambridge, UNITED KINGDOM
Winter, Gregory Paul, Cambridge, UNITED KINGDOM
PATENT ASSIGNEE(S): Medical Research Council (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004058400	A1	20040325	
APPLICATION INFO.:	US 2002-247839	A1	20020920	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: B. J. Sadoff, NIXON & VANDERHYE, 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 5361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 91 USPATFULL on STN
TI Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:69593 USPATFULL
TITLE: Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, UNITED STATES
Matthews, Thomas James, Durham, NC, UNITED STATES
Wild, Carl T., Durham, NC, UNITED STATES
Barney, Shawn O?apos,Lin, Cary, NC, UNITED STATES
Lambert, Dennis Michael, Cary, NC, UNITED STATES
Petteway, Stephen Robert, Cary, NC, UNITED STATES
Langlois, Alphonse J., Durham, NC, UNITED STATES
PATENT ASSIGNEE(S): Duke University (U.S. corporation)
Trimeris, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004052820	A1	20040318	
APPLICATION INFO.:	US 2002-267748	A1	20021008	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat. No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed

on 20 Dec 1994, GRANTED, Pat. No. US 6017536
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994, GRANTED, Pat. No. US 6440656
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, GRANTED, Pat. No. US 5464933

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 83 Drawing Page(s)
LINE COUNT: 40442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 91 USPATFULL on STN
TI Methods of immunotherapy and diagnosis
AB Certain cells, including types of cancer cells such as T-cell lymphoma, T-cell leukemia, multiple myeloma, and chronic myeloid leukemia, B cell lymphoma of mature B cell lineage, non-Hodgkin's lymphoma of mature B-cell lineage, and Burkitt's lymphoma of mature B cell lineage, are capable of expressing SEQ ID NO: 2 or 4-ecoding RNA. Immunotargeting using SEQ ID NO: 2 or 4 polypeptides, nucleic acids encoding for SEQ ID NO: 2 or 4 polypeptides and anti-SEQ ID NO: 2 or 4 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the SEQ ID NO: 2 or 4 protein. Methods of immunotherapy and diagnosis of disorders associated with SEQ ID NO: 2 or 4 protein-expressing cells, such as T-cell lymphoma, T-cell leukemia, multiple myeloma, and chronic myeloid leukemia, B cell lymphoma of mature B cell lineage, non-Hodgkin's lymphoma of mature B-cell lineage, and Burkitt's lymphoma of mature B cell lineage, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64298 USPATFULL
TITLE: Methods of immunotherapy and diagnosis
INVENTOR(S): Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048817	A1	20040311
APPLICATION INFO.:	US 2002-304234	A1	20021126 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-128558, filed on 22 Apr 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339453P	20011211 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Elena Quertermous, NUVELO, 670 Almanor Avenue, Sunnyvale, CA, 94085
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 2808
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 91 USPATFULL on STN
TI Gene expression in bladder tumors
AB Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression

patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:50778 USPATFULL
TITLE: Gene expression in bladder tumors
INVENTOR(S): Orntoft, Torben F., Aabyhoj, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038207	A1	20040226
APPLICATION INFO.:	US 2001-951968	A1	20010914 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 28561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 91 USPATFULL on STN
TI Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:44245 USPATFULL
TITLE: Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
INVENTOR(S): Bolognesi, Dani Paul, Durham, NC, UNITED STATES
Matthews, Thomas James, Durham, NC, UNITED STATES
Wild, Carl T., Durham, NC, UNITED STATES
PATENT ASSIGNEE(S): Duke University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033235	A1	20040219
APPLICATION INFO.:	US 2003-267682	A1	20030106 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat. No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, GRANTED, Pat. No. US 6017536 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994, GRANTED, Pat. No. US 6440656 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, GRANTED, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW

YORK, NY, 100362711
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 63 Drawing Page(s)
LINE COUNT: 59510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 91 USPATFULL on STN
TI Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
AB Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:31728 USPATFULL
TITLE: Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
INVENTOR(S): Dedera, Douglas, Castro Valley, CA, UNITED STATES
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023870	A1	20040205
APPLICATION INFO.:	US 2002-327491	A1	20021219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-302444, filed on 22 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-77676, filed on 14 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2000-687527, filed on 12 Oct 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Renee S. Polizotto, 675 Almanor Avenue, Sunnyvale, CA, 94085
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS, BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT 10:33:36 ON 26 APR 2004
L1 6 S ALBUMIN FUSION PROTEIN () ANTIBODY
L2 521 S HER2 ANTIBODY
L3 0 S ALBUMIN FUSION PROTEIN AND L2
L4 0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY
L5 0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P
L6 6589 S HUMAN EPIDERMAL GROWTH FACTOR

```
L7          875 S L6 AND "RECEPTOR-2"
L8           91 S L7 AND ALBUMIN

=> s l8 and fusion protein
L9          77 L8 AND FUSION PROTEIN

=> s l9 and albumin fusion protein
L10          0 L9 AND ALBUMIN FUSION PROTEIN

=> e rosen, craig/au
E1           1     ROSEN ZWEIG J/AU
E2           1     ROSEN ZWEIG JAMES/AU
E3           0 --> ROSEN, CRAIG/AU
E4           1     ROSENA BRUCE R/AU
E5           1     ROSENABUM S/AU
E6           1     ROSENACKER A F/AU
E7           1     ROSENACKER ARTHUR F/AU
E8           4     ROSENADA CEPERO R/AU
E9           1     ROSENAGER L/AU
E10          2     ROSENAK B/AU
E11         73     ROSENAK B D/AU
E12         31     ROSENAK D/AU

=> e haseltine, W/au
E1          85     HASELTINE WILLIAM A/AU
E2           2     HASELTINE WILLIAM ALAN/AU
E3           0 --> HASELTINE, W/AU
E4           1     HASELTLINE F P/AU
E5           8     HASELTON A/AU
E6           3     HASELTON AARON/AU
E7           1     HASELTON B J/AU
E8           4     HASELTON C/AU
E9           1     HASELTON C B/AU
E10          9     HASELTON C J/AU
E11         37     HASELTON C L/AU
E12          2     HASELTON CAROLE J/AU

=> s e1
L11         85 "HASELTINE WILLIAM A"/AU

=> s e2
L12          2 "HASELTINE WILLIAM ALAN"/AU

=> s l11 and "HER2"
L13          0 L11 AND "HER2"

=> s l12 ti abs ibib tot
MISSING OPERATOR L12 TI
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l12 ti abs ibib tot

L12  ANSWER 1 OF 2  USPATFULL on STN
TI     Nucleic acid encoding HIV-1 tat protein
AB     Nucleic acid encoding a functional HTLV-III/LAV (HIV-1) protein having
       trans-activating ability, and expression vectors comprising this nucleic
       acid are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       1998:104629  USPATFULL
TITLE:                  Nucleic acid encoding HIV-1 tat protein
INVENTOR(S):            Haseltine, William Alan, Cambridge, MA,
                        United States
```

Rosen, Craig A., Brookline, MA, United States
Sodroski, Joseph Gerald, Cambridge, MA, United States
Wong-Staal, Flossie, San Diego, CA, United States
Arya, Suresh K., Gaithersburg, MD, United States
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Boston, MA, United States (U.S. corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5801056		19980901
APPLICATION INFO.:	US 1993-131898		19931005 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-869053, filed on 14 Apr 1992, now abandoned And a continuation-in-part of Ser. No. US 1988-172152, filed on 23 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1985-780925, filed on 27 Sep 1985, now abandoned , said Ser. No. US -869053 which is a continuation of Ser. No. US 1990-604607, filed on 26 Oct 1990, now abandoned which is a division of Ser. No. US 1985-806263, filed on 6 Dec 1985, now patented, Pat. No. US 4981790

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1985-482374	19850524

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Conlin, David G., Eisenstein, Ronald I.Dike, Bronstein, Roberts & Cushman, LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 855
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 2 USPATFULL on STN
TI Assay methods for tat cell lines
AB Assays screened for compounds that inhibit tat transactivation of the HIV (HTLV-III) LTR are taught. The assay involves tranfecting a cell line containing the tat gene by a vector containing a gene under the control of an HIV-1 LTR, adding the compound to be screened and determining the effect of the compound by looking at the effect of tat as measured by the expression of the gene under the control of the HIV LTR.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:104559 USPATFULL
TITLE: Assay methods for tat cell lines
INVENTOR(S): **Haseltine, William Alan**, Cambridge, MA, United States
Rosen, Craig A., Brookline, MA, United States
Sodroski, Joseph Gerald, Cambridge, MA, United States
Goh, Wei Chun, Somerville, MA, United States
PATENT ASSIGNEE(S): Dana Farber Cancer Institute, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800986		19980901
APPLICATION INFO.:	US 1995-456346		19950601 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-213368, filed on 14 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-869053, filed on 14 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-604607, filed on 26 Oct 1990, now abandoned which is a division of Ser. No. US 1985-806263, filed on 6 Dec 1985, now patented, Pat. No. US 4981790 which is a continuation-in-part of Ser. No. US 1984-614297, filed on 25 May 1984, now patented, Pat. No. US 4738922

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1985-432374	19850524
	WO 1985-US985	19850524

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: McKelvey, Terry A.
LEGAL REPRESENTATIVE: Conlin, David C., Eisenstein, Ronald I.Dike, Bronstein, Roberts & Cushman, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 8
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,
     BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT
     10:33:36 ON 26 APR 2004
L1             6 S ALBUMIN FUSION PROTEIN () ANTIBODY
L2           521 S HER2 ANTIBODY
L3             0 S ALBUMIN FUSION PROTEIN AND L2
L4             0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY
L5             0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P
L6          6589 S HUMAN EPIDERMAL GROWTH FACTOR
L7           875 S L6 AND "RECEPTOR-2"
L8            91 S L7 AND ALBUMIN
L9            77 S L8 AND FUSION PROTEIN
L10            0 S L9 AND ALBUMIN FUSION PROTEIN
                 E ROSEN, CRAIG/AU
                 E HASELTINE, W/AU
L11           85 S E1
L12            2 S E2
L13            0 S L11 AND "HER2"

=> s l11 and l1
L14            3 L11 AND L1

=> d l14 ti abs ibib ott
'OTT' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
```

```
            INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
            PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
            entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
            PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
            NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
            CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
            RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
            NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
            PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
            RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
            its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
            its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
            RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
            DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
            INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
            EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
            DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
            without answer number.  SCAN must be entered on the
            same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
            DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
            IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
            ICM, ICS

ENTER DISPLAY FORMAT (STD):d his
'D' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
```

'HIS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must
entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
without answer number. SCAN must be entered on the

```
             same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d his

     (FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,
     BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT
     10:33:36 ON 26 APR 2004
L1             6 S ALBUMIN FUSION PROTEIN () ANTIBODY
L2           521 S HER2 ANTIBODY
L3             0 S ALBUMIN FUSION PROTEIN AND L2
L4             0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY
L5             0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P
L6          6589 S HUMAN EPIDERMAL GROWTH FACTOR
L7           875 S L6 AND "RECEPTOR-2"
L8            91 S L7 AND ALBUMIN
L9            77 S L8 AND FUSION PROTEIN
L10            0 S L9 AND ALBUMIN FUSION PROTEIN
                 E ROSEN, CRAIG/AU
                 E HASELTINE, W/AU
L11           85 S E1
L12            2 S E2
L13            0 S L11 AND "HER2"
L14            3 S L11 AND L1

=> d l14 ti abs ibib tot .

L14  ANSWER 1 OF 3  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2004:13611  USPATFULL
TITLE:                  Albumin fusion proteins
INVENTOR(S):            Rosen, Craig A., Laytonsville, MD, UNITED STATES
                        Haseltine, William A., Washington, DC, UNITED STATES

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2004010134      A1   20040115
APPLICATION INFO.:      US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2000-256931P    20001221 (60)
                        US 2000-199384P    20000425 (60)
```

	US 2000-229358P 20000412 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 2 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)	
	US 2000-199384P	20000425 (60)	
	US 2000-229358P	20000412 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	15415		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ACCESSION NUMBER:         2003:181414  USPATFULL
TITLE:                    Albumin fusion proteins
INVENTOR(S):              Rosen, Craig A., Laytonsville, MD, UNITED STATES
                          Haseltine, William A., Washington, DC, UNITED STATES

                               NUMBER        KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2003125247      A1   20030703
APPLICATION INFO.:        US 2001-833041     A1   20010412  (9)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2000-256931P    20001221 (60)
                          US 2000-199384P    20000425 (60)
                          US 2000-229358P    20000412 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                          ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:         29
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       20 Drawing Page(s)
LINE COUNT:               15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 10:32:57 ON 26 APR 2004)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS, JAPIO, FSTA, JICST-EPLUS,
     BIOBUSINESS, SCISEARCH, CEABA-VTB, CEN, EMBASE, DGENE' ENTERED AT
     10:33:36 ON 26 APR 2004
L1             6 S ALBUMIN FUSION PROTEIN () ANTIBODY
L2           521 S HER2 ANTIBODY
L3             0 S ALBUMIN FUSION PROTEIN AND L2
L4             0 S ALBUMIN FUSION PROTEIN () HER2 ANTIBODY
L5             0 S HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ADJ ALBUMIN FUSION P
L6          6589 S HUMAN EPIDERMAL GROWTH FACTOR
L7           875 S L6 AND "RECEPTOR-2"
L8            91 S L7 AND ALBUMIN
L9            77 S L8 AND FUSION PROTEIN
L10            0 S L9 AND ALBUMIN FUSION PROTEIN
                 E ROSEN, CRAIG/AU
                 E HASELTINE, W/AU
L11           85 S E1
L12            2 S E2
L13            0 S L11 AND "HER2"
L14            3 S L11 AND L1

=> s l11 and albumin fusion protein
L15            3 L11 AND ALBUMIN FUSION PROTEIN

=> d l15 ti abs ibib tot

L15  ANSWER 1 OF 3  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
```

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:13611 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010134	A1	20040115	
APPLICATION INFO.:	US 2001-833245	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	18 Drawing Page(s)			
LINE COUNT:	25066			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 3 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219875	A1	20031127	
APPLICATION INFO.:	US 2001-833118	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	29			

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 3 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.